Navigation Links
Zevalin Data to be Presented at ASH 2008
Date:12/3/2008

90-Ibritumomab Tiuxetan (Zevalin(R)) with Autograft: Lack of Detection of Remarkable Abnormalties. Sunday Dec. 7, 2008 6:00-8:00 PM 2187 Poster II-281 Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90Y-Ibritumomab Tiuxetan Sunday Dec. 7, 2008 6:00-8:00 PM 2995 Poster III-77 Dose Escalated Radioimmunotherapy with Yttrium-90-Ibritumomab Tiuxetan as Part of a Reduced Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Aggressive Non- Hodgkin Lymphoma: An Interim Analysis of a Phase I/II Study Monday, Dec. 8, 2008 5:30-7:30 PM 3056 Poster III-138 R-FND Followed by Radioimmunotherapy for High- Risk Follicular Lymphoma Monday, Dec. 8, 2008 5:30-7:30 PM 3598 Poster III-680 Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
4. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
5. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
6. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
7. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
8. Success of Shape Up Somerville childhood obesity intervention to be presented
9. Survival data presented from phase II study of hormone-resistant prostate cancer patients
10. Special Olympics Special Spirit in China Award Of Excellence Presented to Dedicated Friends of Special Olympics and City of Shanghai
11. UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...Increase in Patients Unable to Pay Out-of-Pocket C...ng Hospital ERs , , SACRAMENTO, Calif., Jan. 7 ...ving a dramatic impact on California,s community h...port by the California Hospital Association (CHA)....ucted in November 2008 among hospital chief financ...
(Date:1/7/2009)...e Support and Convenience , , CARLSBAD, Calif., ...ch of a new on-line service for physicians and pat...rmation and products. The new Web site, www.skinm...ents and their physicians while offering the conve...(Photo: http://www.newscom.com/cgi-bin/prnh/2009...
(Date:1/7/2009)...ailure, slowed cell growth, study says , ,...drug used for many years to treat irregular heart ...ghting agent, researchers report. , Cancer cells n...ny of these cells are oxygen-deprived and need to ...xia-inducible factor (HIF-1), which help cells sur...
(Date:1/7/2009)...Foundation recently awarded two core faculty membe...ics a grant that will allow Drs. Gail Geller and C...ges health professionals face while caring for chi...uromuscular diseases (LTNMD). , The concept for t... international HeartSongs Project funded by the St...
Breaking Medicine News(10 mins):Health News:Economic Downturn Takes Toll on California Hospitals 2Health News:SkinMedica Launches On-Line Service for Physician Partners 2Health News:Heart Drug May Be a Cancer Fighter 2Health News:Study to explore ethical challenges health professionals face while caring for children with LTNMDs 2Health News:Study to explore ethical challenges health professionals face while caring for children with LTNMDs 3
...ible for Type 2 diabetes scientists have come clos.... The PSARL gene associated with the Type 2 diabe... Washington tomorrow. Diabetes, now considered as...100,000 Australians every year costing Australian ...
...cer-causing virus enables it to bypass immune syst...es an unusual gene and also ensures that the virus... function of a protein called HBZ, which is made b... 1 (HTLV-1), a retrovirus and a distant cousin to ...
...incidence of drug abuse in the 16 to 35 age group ...re unemployment is rampant, according to a study. ...ogical Study", released by Punjab Governor S F Rod...number of youth in the villages of Punjab were tak...
...start a health insurance policy next month which w...panies that fall under the Phase 1 category will b...eme // which will make the lowest paid the first t... Al Mazroui, Director General of the General Autho...
Other Medicine News:Health News:Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells 2Health News:Cancer-Causing Virus Synthesizes Protein To Help Sustain Itself In Host Cells 3
(Date:1/7/2009)..., Late Preterm Infants Drive the Increase , ,.../ -- New government statistics confirm that the de... rate continues, putting more infants than ever at...to the March of Dimes. , , Nearly 543,000 babie...ional Center for Health Statistics, which today re...
(Date:1/7/2009)..., OXFORD, England, January 7 ...pany focused on allergy and critical care, today,...ts achieved in 2008 with,its ToleroMune(R) anti-a...patient recruitment for a further phase II clinica...way in Canada, has recruited 120 patients with con...
(Date:1/6/2009)..., NEW YORK, Jan. 6 Th...ut $2.7 million to four industry research teams fo...s for Parkinson,s disease. , , The funding was ...opment Initiative. This program, first launched i...orts on Parkinson,s research. TDI is part of MJF...
(Date:1/6/2009)..., PARIS, France, January 6 /PRNewswire-First... to Extend the Collaboration Until,December 2011 ...tion to Include Antibody,Discovery in Ophthalmolo...s to ExonHit if Allergan,Sublicenses to a Third P...LEHT) today announced a reinforcement,of its exis...
Breaking Medicine Technology:Preterm Births Rise 36 Percent Since Early 1980s 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 17828 1Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 17828 2Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 17828 3Thermage Inc Announces First Quarter 2008 Results Release Date and Conference Call 17826 1Clinical Update Debio 025 in Hepatitis C 1907 1Clinical Update Debio 025 in Hepatitis C 1907 2Clinical Update Debio 025 in Hepatitis C 1907 3NAMI 3A Women and Depression 3B 1 in 8 in Their Lifetime 3B Twice the Rate of Men 17822 1NAMI 3A Women and Depression 3B 1 in 8 in Their Lifetime 3B Twice the Rate of Men 17822 2
...S WIRE)--May 14, 2007 - Oculus Innovative,Sciences...cyn,Technology was the subject of a poster present... (EWMA) conference that was held in,Glasgow, Scotl... Results About an Antimicrobial,Solution in the Tr...ng & Harding infection criteria to evaluate th...
...-May 15, 2007 - Gemin X Biotechnologies,Inc. annou...Blood,demonstrated that its lead compound, obatocl...le Cell Lymphoma (MCL) cell lines and,primary cell...small,molecule specifically designed to inhibit al...validated cancer target, thus restoring,the natura...
Other Medicine Technology:Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 2Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference 3Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
...ttors , , Available with five different volume ra...ors can effectively meet the demands of any applic...nd superior functionality as our multichannel line...a wide range of liquid handling tasks including:,...
... high performance electronic pipetting!, Soft, f...educe hand fatigue and strain , Stress-free tip ...ding for easy volume identification , Accepts un...on AdvanTip Low Retention and AdvanTip Precision P...
... high performance electronic pipetting! , Soft, ...reduce hand fatigue and strain, Stress-free tip ...ing for easy volume identification, Accepts univ... AdvanTip Low Retention and AdvanTip Precision Pip...
The Finnpipette BioControl is a major step forward in electronic pipetting technology. A complete liquid handling system - with one universal handle and twelve interchangeable tip cone modules. All f
Medicine Products: